Linagliptin: A novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy

Advances in Therapy

Volumn 28, Issue 6, 2011, Pages 447-459

  Barnett, Anthony H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

DPP 4 inhibitor; glycemic control; linagliptin; renal impairment; type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; VOGLIBOSE;

CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME DEGRADATION; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IC 50; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; PURINES; QUINAZOLINES;

EID: 79958230306     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0028-y     Document Type: Review

References (36)

1. International Diabetes Federation. Diabetes Atlas. 4th edition. Available at: www.diabetesatlas.org. Accessed November 1, 2010.
2. Yorkshire & Humber Public Health Observatory. APHO diabetes prevalence model. Available at: www.yhpho.org.uk/resource/view.aspx?RID=81090. Accessed November, 2010.
3. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988-2994. (Pubitemid 41401097)
4. Kirby M, Yu DM, O'Connor S, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci. 2010;118:31-41.
5. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Experimental Therapeut. 2008;325:175-182. (Pubitemid 351439162)
6. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11:786-794.
7. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667-678.
8. Retlich S, Duval V, Ring A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet. 2010;49:829-840.
9. Scheen AJ. Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010;49:573-588.
10. Graefe-Mody U, Friedrich C, Port A, et al. Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment. Poster 822-P, European Association for the Study of Diabetes Annual Meeting, 20-24 September 2010, Stockholm, Sweden.
11. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor. Clin Pharmacol Therapeut. 2006;38:PII-46.
12. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10:545-555. (Pubitemid 351850898)
13. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30:513-527. (Pubitemid 351492530)
14. Del Prato S, Barnett AH, Huismann H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes. Diabetes Obes Metab. 2011;13:258-267.
15. Taskinen M-R, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, placebo controlled study. Diabetes Obes Metab. 2011;13:65-74.
16. Owens DR, Swallow R, Woerle HJ, et al. Linagliptin improves glycaemic control in type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain and low risk of hypoglycaemia. Poster 548-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA.
17. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, placebo controlled study. Diabetes Obes Metab. 2011;doi: 10.1111/j.1463-1326.2011.01391.x.
18. Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Poster 821-P, European Association for the Study of Diabetes Annual Meeting, 20-24 September 2010, Stockholm, Sweden.
19. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Poster 696-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA.
20. Kawamori R, Inagaki N, Araki E, et al. Linagliptin provides superior glycemic control compared to voglibose as monotherapy in Japanese patients with type 2 diabetes. Poster 632-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA.
21. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabetic Med. 2010;27:1409-1419.
22. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
23. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206. (Pubitemid 47057766)
24. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-294. (Pubitemid 36775376)
25. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
26. Shah P, Schumann DM, Ardestani A, et al. The DPP-4 inhibitor linagliptin restores β-cell function in human isolated islets. Poster 1742-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA.
27. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741-750. (Pubitemid 36323582)
28. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol. 2011;650:703-707.
29. National Kidney Foundation. Diabetes and Chronic Kidney Disease; Stages 1-4. Available at: www.kidney.org/atoz/pdf/diabetes.pdf. Accessed November, 2010.
30. Tayside Diabetes MCN Handbook. Pharmalogical management of glycaemic control in people with type 2 diabetes. Available at: www.diabetes-healthnet.ac. uk/HandBook/TreatementsWithHypoAgents2.aspx. Accessed November 1, 2010.
31. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
32. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673-682.
33. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436-2440. (Pubitemid 41384290)
34. Koopman RJ, Mainous AG 3rd, Liszka HA, et al. Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med. 2006;4:427-432. (Pubitemid 44544149)
35. Barnett AH. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;11:1454-1470.
36. National Institute for Health and Clinical Excellence (NICE). CG87 type 2 diabetes - newer agents (May 2009). Available at: www.nice.org.uk/nicemedia/ live/12165/44318/44318.pdf. Accessed November 1, 2010.